MedTrace Logo

Clinical Trial of Favipiravir Treatment of Patients With COVID-19

NCT04600999 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-11-01

No results posted yet for this study

Summary

To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint.

Conditions

Interventions

DRUG

Favipiravir

Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]

Sponsors & Collaborators

  • HECRIN Consortium

    collaborator UNKNOWN

  • Hungarian Ministry of Innovation and Technology

    collaborator UNKNOWN

  • University of Pecs

    lead OTHER

Principal Investigators

  • István Várkonyi · Institute of Infectology University of Debrecen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2020-12-28
Completion
2020-12-28

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04600999 on ClinicalTrials.gov